(Q38016230)

27 August 2017

title

Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us? (English)

1 reference

27 August 2017

0 references

David M Taylor

2

0 references

author name string

Azizah Attard

series ordinal

1

1 reference

27 August 2017

publication date

1 June 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

26

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

491-508

1 reference

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Results of phase 3 of the CATIE schizophrenia trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Extrapyramidal side-effects of antipsychotics in a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Clinical trials design lessons from the CATIE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Quetiapine: dose-response relationship in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Dropout rates in randomised antipsychotic drug trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Evidence That Early Extrapyramidal Symptoms Predict Later Tardive Dyskinesia: A Prospective Analysis of 10,000 Patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632020-000000000-00000

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia

21 January 2018

1 reference

12 December 2020

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

1 reference

12 December 2020

Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study

1 reference

12 December 2020

Effectiveness of switching antipsychotic medications

1 reference

12 December 2020

The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.

1 reference

12 December 2020

Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

1 reference

12 December 2020

Implications of the CATIE trial on treatment: extrapyramidal symptoms

1 reference

12 December 2020

The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics.

1 reference

12 December 2020

Lessons to take home from CATIE.

1 reference

12 December 2020

Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.

1 reference

12 December 2020

What CATIE found: results from the schizophrenia trial

1 reference

12 December 2020

The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

1 reference

12 December 2020

A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.

1 reference

12 December 2020

Metabolic considerations in the use of antipsychotic medications: a review of recent evidence

1 reference

12 December 2020

A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

1 reference

12 December 2020

Sulpiride for schizophrenia

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

12 December 2020

Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol

1 reference

12 December 2020

Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).

1 reference

12 December 2020

The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment

1 reference

12 December 2020

10.2165/11632020-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1009550092

0 references

1 reference